27833-64-3
27833-64-3 structure
- Name: Loxapine succinate
- Chemical Name: loxapine succinate
- CAS Number: 27833-64-3
- Molecular Formula: C22H24ClN3O5
- Molecular Weight: 445.896
- Catalog: Biochemical Inhibitor Neuronal Signaling 5-HT Receptor Antagonist
- Create Date: 2018-03-22 08:00:00
- Modify Date: 2026-07-02 12:38:14
-
Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent.IC50 value: Target: D2DR/D4DR; 5-HT receptorin vitro: In the presence of Loxapine, [3H]ketanserin binds to 5-HT2 receptor in Frontal cortex of brain in human and bovine with ki value of 6.2 nM and 6.6 nM, respectively. Loxapine has the rank order of potency for the various receptors appears to be as follows:5-HT2≥D4>>>D1>D2 in comparing competition experiments involving the human membranes [1]. Loxapine 0.2 μM, 2 μM and 20 μM reduces IL-1beta secretion by LPS-activated mixed glia cultures after 1 and 3 days of exposure. Loxapine in concentrations of 0.2 μM, 2 μM and 20 μM reduces IL-2 secretion in mixed glia cultures after 1 and 3 days of exposure, and additionally Loxapine decreases IL-1beta and IL-2 secretion in LPS-induced microglia cultures in concentrations of 2 μM, 10 μM and 20 μM [2].in vivo: Loxapine (5 mg/kg) induces a very significant reduction (more than 50%) of serotonin (S2) receptor density after 4 weeks or 10 weeks of daily injection in the rat. Loxapine (5 mg/kg) does not change dopamine receptor density but greatly reduces serotonin receptor density by 47% in the brain of rats [3].
| Name | loxapine succinate |
|---|---|
| Synonyms |
2-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine succinate (1:1)
Succinic acid - 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine (1:1) succinic acid, compound with 2-chloro-11-(4-methylpiperazin-1-yl)dibenz[b,f][1,4]oxazine (1:1) 6,9-Dihydro-2-chloro-11-(4-methylpiperazino)dibenz[b,f][1,4]oxazine acide butanedioïque - 2-chloro-11-(4-méthylpipérazin-1-yl)dibenzo[b,f][1,4]oxazépine (1:1) MFCD00069298 Loxapine Succinate Capsules Loxapine succina loxitane LOXAPINE SUCCINATE DIBENZOXAZINE ANTIP 2-CHLORO-11-(4-METHYL-1-PIPERAZINYL)-DIBENZ[B,F][1,4]-OXAZINE SUCCINATE Cloxazin Oxilapine Loxapine succinate solution Loxapine succinate salt //BP Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-, butanedioate (1:1) CL-62362 butanedioic acid,8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine butanedioate Lederle oxazine(1:1) 2-Chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine succinate loxapac dopamine rector Loxapine (succinate) Butanedioic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazine (1:1) Loxapine.succinate, 1mg/ml in Methanol (as free base) Loxapine Succinate saltQ: What is Loxapine Succinate salt Q: What is the CAS Number of Loxapine Succinate salt Q: What is the storage condition of Loxapine Succinate salt cl71563 LOXAPINE SUCCINATE SALT LOXAPINE SUCCINATE Daxolin succinicacid,compd.with2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazine(1:1) Butandisäure--2-chlor-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepin(1:1) succinicacid,compd.with2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4) Loxitane Loxapine succinate salt, 25 ade Loxapac EINECS 248-682-0 succinic acid 2-chloro-11-(4-methylpiperazin-1-yl)dibenz[b,f][1,4]oxazine salt Calcium Cbonate Tablets lederle Loxapine succinate, 10 mM in DMSO loxapine succinate salt Lidocaine succinate a 5-HT inhibitor S-805 Cloxazepin Loxapine succinate, >= daxoline 8-chloro-6-(4-methyl-1-piperazin-1-iumylidene)-5H-benzo[b][1,4]benzoxazine SUM-3170 SUM-317 LIDOCAINE SUCCINATE LOXAPINESUCCINATE |
| Description | Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent.IC50 value: Target: D2DR/D4DR; 5-HT receptorin vitro: In the presence of Loxapine, [3H]ketanserin binds to 5-HT2 receptor in Frontal cortex of brain in human and bovine with ki value of 6.2 nM and 6.6 nM, respectively. Loxapine has the rank order of potency for the various receptors appears to be as follows:5-HT2≥D4>>>D1>D2 in comparing competition experiments involving the human membranes [1]. Loxapine 0.2 μM, 2 μM and 20 μM reduces IL-1beta secretion by LPS-activated mixed glia cultures after 1 and 3 days of exposure. Loxapine in concentrations of 0.2 μM, 2 μM and 20 μM reduces IL-2 secretion in mixed glia cultures after 1 and 3 days of exposure, and additionally Loxapine decreases IL-1beta and IL-2 secretion in LPS-induced microglia cultures in concentrations of 2 μM, 10 μM and 20 μM [2].in vivo: Loxapine (5 mg/kg) induces a very significant reduction (more than 50%) of serotonin (S2) receptor density after 4 weeks or 10 weeks of daily injection in the rat. Loxapine (5 mg/kg) does not change dopamine receptor density but greatly reduces serotonin receptor density by 47% in the brain of rats [3]. |
|---|---|
| Related Catalog | |
| References |
| Boiling Point | 458.6ºC at 760mmHg |
|---|---|
| Melting Point | 150-152°C |
| Molecular Formula | C22H24ClN3O5 |
| Molecular Weight | 445.896 |
| Flash Point | 231.1ºC |
| Exact Mass | 445.140442 |
| PSA | 102.67000 |
| LogP | 3.01860 |
| Storage condition | -20°C Freezer |
| Water Solubility | H2O: soluble |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | Xi |
| RIDADR | UN 2811 6.1 / PGII |
| WGK Germany | 3 |
| RTECS | WM5750000 |